Status:

UNKNOWN

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Lead Sponsor:

Ain Shams University

Conditions:

Lupus Nephritis

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

PHASE2

Brief Summary

The aim of this study is to assess the safety and efficacy of SGLT2is among LN patients.

Detailed Description

SLE is a chronic debilitating autoimmune disorder that involves multiple organ systems either simultaneously or sequentially with relapsing and remitting course. The word 'Lupus' is a Latin term which...

Eligibility Criteria

Inclusion

  • Patients aged more than 18 year.
  • Patients with confirmed SLE according to EULAR/ACR classification criteria.
  • Patients with LN ( persistent proteinuria \> 2 gm per day or greater than 3+ by dipstick, and/or cellular casts including red cell, hemoglobin, granular, tubular or mixed \& "active urinary sediment" (\>5 RBC/hpf, \>5 WBC/hpf in the absence of infection, or cellular casts limited to RBC or WBC casts )
  • Patient with e GFR \> 25 ml/min/1.73m2 by CKD-EPI equation.

Exclusion

  • Patients with an allergy or intolerance to Dapagliflozin or any prior SGLT2i exposure within 1 month before screening.
  • Medical history of chronic disease (Severe respiratory distress, gastrointestinal tract lesions \& chronic liver disease)
  • Patients with recurrent genitourinary infections.
  • Patient with proteinuria \< 2gm.
  • Patient who show response to immune therapy in proteinuria reduction \> 50%.
  • Patient with Lupus in induction phase.
  • Patient on steroids \> 30 mg daily dose.
  • Patients with diabetes mellitus.
  • Patients with severe infection requiring antibiotics within 1 month before screening.
  • Patients with malignant diseases.
  • Pregnant or breast-feeding women.
  • Patients with eGFR \< 25 ml/min/1.73m2 or undergoing dialysis therapy

Key Trial Info

Start Date :

December 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 30 2025

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06113900

Start Date

December 1 2023

End Date

January 30 2025

Last Update

November 2 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ain Shams University

Alexandria, Egypt